OBJECTIVE: An inversion polymorphism of approximately 900 kb on chromosome 17q21, which includes the microtubule-associated protein tau (MAPT) gene defines two haplotype clades, H1 and H2. Several small case-control studies have observed a marginally significant excess of the H1/H1 diplotype among patients with Parkinson's disease (PD), and one reported refining the association to a region spanning exons 1 to 4 of MAPT. We sought to replicate these findings. METHODS: We genotyped 1,762 PD patients and 2,010 control subjects for a single nucleotide polymorphism (SNP) that differentiates the H1 and H2 clades. We also analyzed four SNPs that define subhaplotypes within H1 previously reported to associate with PD or other neurodegenerative disorders. RESULTS: After adjusting for age, sex, and site, we observed a robust association between the H1/H1 diplotype and PD risk (odds ratio for H1/H1 vs H1/H2 and H2/H2, 1.46; 95% confidence interval, 1.25-1.69; p = 8 x 10(-7)). The effect was evident in both familial and sporadic subgroups, men and women, and early- and late-onset disease. Within H1/H1 individuals, there was no significant difference between cases and control subjects in the overall frequency distribution of H1 subhaplotypes. INTERPRETATION: Our data provide strong evidence that the H1 clade, which contains MAPT and several other genes, is a risk factor for PD. However, attributing this finding to variants within a specific region of MAPT is premature. Thorough fine-mapping of the H1 clade in large numbers of individuals is now needed to identify the underlying functional variant(s) that alter susceptibility for PD.
OBJECTIVE: An inversion polymorphism of approximately 900 kb on chromosome 17q21, which includes the microtubule-associated protein tau (MAPT) gene defines two haplotype clades, H1 and H2. Several small case-control studies have observed a marginally significant excess of the H1/H1 diplotype among patients with Parkinson's disease (PD), and one reported refining the association to a region spanning exons 1 to 4 of MAPT. We sought to replicate these findings. METHODS: We genotyped 1,762 PDpatients and 2,010 control subjects for a single nucleotide polymorphism (SNP) that differentiates the H1 and H2 clades. We also analyzed four SNPs that define subhaplotypes within H1 previously reported to associate with PD or other neurodegenerative disorders. RESULTS: After adjusting for age, sex, and site, we observed a robust association between the H1/H1 diplotype and PD risk (odds ratio for H1/H1 vs H1/H2 and H2/H2, 1.46; 95% confidence interval, 1.25-1.69; p = 8 x 10(-7)). The effect was evident in both familial and sporadic subgroups, men and women, and early- and late-onset disease. Within H1/H1 individuals, there was no significant difference between cases and control subjects in the overall frequency distribution of H1 subhaplotypes. INTERPRETATION: Our data provide strong evidence that the H1 clade, which contains MAPT and several other genes, is a risk factor for PD. However, attributing this finding to variants within a specific region of MAPT is premature. Thorough fine-mapping of the H1 clade in large numbers of individuals is now needed to identify the underlying functional variant(s) that alter susceptibility for PD.
Authors: Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee Journal: Science Date: 2003-04-25 Impact factor: 47.728
Authors: D M Maraganore; D G Hernandez; A B Singleton; M J Farrer; S K McDonnell; M L Hutton; J A Hardy; W A Rocca Journal: Ann Neurol Date: 2001-11 Impact factor: 10.422
Authors: Rohan de Silva; John Hardy; Julia Crook; Naheed Khan; Elizabeth A Graham; Christopher M Morris; Nicholas W Wood; Andrew J Lees Journal: Neurosci Lett Date: 2002-09-20 Impact factor: 3.046
Authors: Lorraine N Clark; Gilberto Levy; Ming-Xin Tang; Helen Mejia-Santana; Alejandra Ciappa; Benjamin Tycko; Lucien J Cote; Elan D Louis; Richard Mayeux; Karen Marder Journal: Neurosci Lett Date: 2003-08-14 Impact factor: 3.046
Authors: Beata Pepłońska; Cezary Zekanowski; Dorota Religa; Krzysztof Czyzewski; Maria Styczyńska; Anna Pfeffer; Tomasz Gabryelewicz; Marek Gołebiowski; Elzbieta Luczywek; Boguslaw Wasiak; Anna Barczak; Małgorzata Chodakowska; Maria Barcikowska; Jacek Kuźnicki Journal: Neurosci Lett Date: 2003-09-18 Impact factor: 3.046
Authors: M Zappia; G Annesi; G Nicoletti; P Serra; G Arabia; P Pugliese; D Messina; M Caracciolo; N Romeo; F Annesi; A A Pasqua; P Spadafora; D Civitelli; N Romeo; A Epifanio; L Morgante; A Quattrone Journal: Neurol Sci Date: 2003-10 Impact factor: 3.307
Authors: Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami Journal: J Neurol Neurosurg Psychiatry Date: 2010-09-30 Impact factor: 10.154
Authors: D M Kay; C F Stevens; T H Hamza; J S Montimurro; C P Zabetian; S A Factor; A Samii; A Griffith; J W Roberts; E S Molho; D S Higgins; S Gancher; L Moses; S Zareparsi; P Poorkaj; T Bird; J Nutt; G D Schellenberg; H Payami Journal: Neurology Date: 2010-09-28 Impact factor: 9.910
Authors: Colin C McCulloch; Denise M Kay; Stewart A Factor; Ali Samii; John G Nutt; Donald S Higgins; Alida Griffith; John W Roberts; Berta C Leis; Jennifer S Montimurro; Cyrus P Zabetian; Haydeh Payami Journal: Hum Genet Date: 2008-01-22 Impact factor: 4.132
Authors: James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine Journal: Curr Top Med Chem Date: 2009 Impact factor: 3.295
Authors: Melissa E Murray; Neill R Graff-Radford; Owen A Ross; Ronald C Petersen; Ranjan Duara; Dennis W Dickson Journal: Lancet Neurol Date: 2011-07-27 Impact factor: 44.182
Authors: Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami Journal: Mov Disord Date: 2011-06-28 Impact factor: 10.338
Authors: Anna-Lotta Kaivorinne; Johanna Krüger; Katja Kuivaniemi; Hannu Tuominen; Virpi Moilanen; Kari Majamaa; Anne M Remes Journal: BMC Neurol Date: 2008-12-17 Impact factor: 2.474